🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

As rare disease drug development faces headwinds – from layoffs at the FDA to uncertainty around renewal of Rare Pediatric Disease Priority Review Voucher program – the stakes for innovation have never been higher. “Every single day matters,” Alltrna CEO Michelle Werner tells

Proud to see Alltrna scientists sharing their work at two Gordon Research Conferences! We’re honored to contribute to the scientific dialogue driving forward innovation in tRNA therapeutics. #tRNA #RNA #tRNAmedicines #tRNAbiology #rarediseases #raredisease #StopCodonDisease

𝗥𝗲𝘄𝗿𝗶𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝘁𝗥𝗡𝗔. Exciting to see Drug Discovery News highlight Alltrna’s pioneering work in tRNA-based therapeutics. Our mission is to develop a single tRNA medicine that can address hundreds

We are pleased to announce that Alltrna will present new preclinical data for the company’s lead drug candidate, AP003, at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The presentation, titled 𝙩𝙍𝙉𝘼 𝙖𝙩 𝙩𝙝𝙚 𝙁𝙧𝙤𝙣𝙩𝙞𝙚𝙧:

It’s PKU Awareness Month, and Alltrna is moving with purpose! 👟We're proud to sponsor and participate in Move Your Pheet, a month-long event supporting the NPKUA and families affected by phenylketonuria (PKU), a rare metabolic disorder that demands constant, life-long

Alltrna will be at TIDES USA, where Caroline Köhrer, Ph.D., SVP, Discovery Platform, will present preclinical data supporting the potential of #tRNA therapeutics to restore full-length protein synthesis in diseases caused by premature termination codons. Caroline will discuss how

𝙍𝙖𝙞𝙙𝙚𝙧𝙨 𝙤𝙛 𝙩𝙝𝙚 𝙇𝙤𝙨𝙩 𝘾𝙤𝙙𝙤𝙣? #tRNA may be ancient, but its therapeutic future is just beginning. In this new Advancing RNA article, Alltrna CEO Michelle Werner unpacks how we’re harnessing the tRNA’s universal biology to potentially treat many diseases with the

We’re proud to share that Alltrna CEO, Michelle Werner, will deliver a 𝗦𝘁𝗮𝘁𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗿𝘁 𝗟𝗲𝗰𝘁𝘂𝗿𝗲 at the ASCPT 2025 Annual Meeting. Michelle will speak on the theme: “𝙋𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝘿𝙚𝙨𝙚𝙧𝙫𝙚 𝘽𝙚𝙩𝙩𝙚𝙧: 𝙃𝙖𝙧𝙣𝙚𝙨𝙨𝙞𝙣𝙜 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙤𝙣 𝙖𝙣𝙙

We’re looking forward to joining the Duchenne community at CureDuchenne's #FUTURES2025 to discuss the role of nonsense mutations—also known as premature termination codons—in driving disease, and how Alltrna’s tRNA medicines are uniquely positioned to address them. Alltrna CEO

Today on #ClinicalTrialsDay, we recognize the critical role of clinical trials in bringing new therapies to patients—especially across rare diseases. The numbers tell a clear story: 𝟵𝟱% 𝗼𝗳 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗵𝗮𝘃𝗲 𝗻𝗼 𝗙𝗗𝗔-𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝘆.

With State of the Art and Featured Speakers like Michelle Werner of @Alltrna, Colin Pillai, and Brian Corrigan, #ASCPT2025 is jam packed with exciting scientific content! bit.ly/3Hb77nq

We’ve moved! Alltrna is now in our new labs and offices – a space for bold science and big ideas. Here's to the next chapter in pioneering tRNA therapeutics and building a new future for patients. alltrna.com/life-at-alltrna

We’ve been walking together throughout May to support the PKU community as part of #MoveYourPheet. It’s been an incredible way to connect as a team while raising awareness for those living with phenylketonuria (PKU), a lifelong rare condition that still lacks targeted treatments.

What if one medicine could treat hundreds or thousands of rare genetic diseases? That bold idea is what brought Michelle Werner to Alltrna. In this episode of the Business of Biotech podcast, Michelle shares how her experience as a rare disease parent shaped her decision to lead